01.26.12
Celgene to Acquire Avila Therapeutics

01.19.12
Avila Announces FDA Allowance of Partner Clovis Oncology's IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor

01.03.12
Avila Therapeutics to Present at J.P. Morgan Healthcare Conference

12.12.11
Avila Therapeutics Presents Data on AVL-292, a selective Bruton's Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 ASH Annual Meeting

12.05.11
Avila Therapeutics to Present at the 2011 American Society of Hematology Annual Meeting

11.08.11
Avila Therapeutics Presents Clinical and PreClinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting

11.07.11
Avila to Present at Lazard Capital Markets 8th Annual Healthcare Conference

09.14.11
Avila Completes Dosing of First Patient Cohort in Phase 1b Clinical Study of AVL-292, a Selective Bruton's Tyrosine Kinase Inhibitor for the Treatment of B Cell Cancers

09.12.11
Avila to Present at UBS Global Healthcare Life Sciences Conference

09.05.11
Avila to Present at Stifel Nicolaus 2011 Healthcare Conference

08.10.11
Avila Therapeutics Moves to a New, Larger Facility

07.20.11
Avila is Granted its First U.S. Patent Covering a Class of Targeted Covalent Drugs

07.11.11
Avila Appoints Andrew Hirsch as Chief Financial Officer

06.23.11
Avila Therapeutics Presents Preclinical Data with AVL-292, its BTK Inhibitor, Demonstrating Suppression of Autoimmune Disease Activity

06.10.11
Avila Therapeutics Presents Data Demonstrating the Relevance of its Btk Inhibitor, AVL‐292, in B Cell Malignancies such as CLL

06.08.11
Avila Announces Agreement with the National Institute of Allergy and Infectious Diseases

06.08.11
Avila Announces Selection of Clinical Drug Candidate in EGFR Mutant-Selective Inhibitor Alliance with Clovis Oncology

04.06.11
Avila Therapeutics Announces Positive Data for Btk Inhibitor, AVL-292, in Phase 1a Studies

04.05.11
Avila Presents Data on Novel PI3K-alpha Inhibitor Designed as a Targeted Covalent Drug at American Assoication for Cancer Research Annual Meeting

04.01.11
Avila Scientists Publish "The Resurgence of Covalent Drugs" in Nature Reviews Drug Discovery

03.30.11
Avila Therapeutics to Present at the Needham Healthcare Conference

03.23.11
Avila Therapeutics to Present at the 241st American Chemical Society National Meeting

03.02.11
Avila Therapeutics to Present at 31st Annual Cowen Healthcare Conference